Abstract
Background Lipocalin-2 (LCN2), a protein secreted mainly by activated neutrophils, has been associated with neurodegeneration, obesity, and inflammatory responses. Serum LCN2 concentration has been reported elevated in patients with psoriasis, but lower in patients with atopic dermatitis (AD). Spinal astrocyte-derived LCN2 was found to be involved in enhancement of itch in a mouse model of AD. However, the relationship between LCN2 and itch in patients with psoriasis has not been determined. Objective. This study examined the correlation between serum LCN2 levels and the degrees of itch in patients with psoriasis. Methods Serum LCN2 concentrations were measured by enzyme-linked immunosorbent assays (ELISA) in patients with psoriasis and AD and in healthy controls. The degree of itch was assessed using a visual analog scale (VAS), and disease severity was determined by measuring psoriasis area and severity index (PASI) and scoring atopic dermatitis (SCORAD). Correlations among serum LCN2 level, VAS, PASI, and SCORAD were analyzed statistically. We further examined the serum LCN levels in psoriasis patients before and after biological treatment. Results Serum LCN2 concentrations were significantly higher in patients with psoriasis and AD than those in healthy controls. In patients with psoriasis, serum LCN2 concentrations were significantly correlated with VAS, but not with PASI. In contrast, serum LCN2 concentrations did not correlate with VAS or SCORAD in patients with AD. Serum LCN2 levels in psoriasis patients significantly decreased after the biological treatment along with improvement of VAS. Conclusion Serum LCN2 concentration is associated with the degree of itch in patients with psoriasis, suggesting that serum LCN2 may be a useful clinical marker for itch in psoriasis.
Highlights
Itch is defined as an unpleasant sensation inducing a desire to scratch
enzyme-linked immunosorbent assays (ELISA) measurements showed that serum LCN2 concentrations were significantly higher in patients with psoriasis (80 08 ± 51 3 ng/ml) and atopic dermatitis (AD) (78 32 ± 43 42 ng/ml) than those in healthy controls (59 07 ± 20 18 ng/ml, P < 0 05 each), but there was no significant deference in serum LCN2 levels between psoriasis and AD patients (Figure 1)
Serum LCN2 levels were significantly higher in psoriatic patients with than without itch (88 72 ± 51 45 ng/ml vs. 56 86 ± 44 44 ng/ml, P < 0 05) (Figure 2(a)), but there was no correlation between serum LCN2 levels and disease severities (PASI or scoring atopic dermatitis (SCORAD)) (Figures 2(b) and 2(c))
Summary
Itch is defined as an unpleasant sensation inducing a desire to scratch. Psoriasis is a chronic inflammatory skin disease accompanied by itch in about 60-90% of patients [1,2,3,4,5,6]. LCN2 derived from spinal astrocytes has been found to enhance itch in a mouse model of atopic dermatitis (AD) [14]. Serum LCN2 concentration has been reported higher in patients with psoriasis, but lower in patients with AD, than that in healthy controls [15, 16]. This study examined the correlation between serum LCN2 levels and the degrees of itch in patients with psoriasis. Serum LCN2 concentrations were significantly higher in patients with psoriasis and AD than those in healthy controls. Serum LCN2 concentrations were significantly correlated with VAS, but not with PASI. Serum LCN2 concentrations did not correlate with VAS or SCORAD in patients with AD. Serum LCN2 levels in psoriasis patients significantly decreased after the biological treatment along with improvement of VAS. Serum LCN2 concentration is associated with the degree of itch in patients with psoriasis, suggesting that serum LCN2 may be a useful clinical marker for itch in psoriasis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
